Company intelligence / Profile preview

Ascil Biopharm

Cerdanyola del Vallès, Catalonia, Spainascil-biopharm.com ↗

Ownership: Private
Employees: ~25
Development stage: Phase 1

Overview

No specific clinical results disclosed. The company has a proven track record in developing injectable drug delivery systems with more than fifty patent families covering hundreds of DDS formulations and device patents. They support both internal R&D programs and external client projects from preclinical to early clinical stages.

Therapeutic areas: OncologyEndocrinologyDermatologyOphthalmologyInfectious Diseases
Modalities: PeptidesProteinsFusion proteinsToxinsMonoclonal antibodyBiologicInjectable solutions (Drug delivery modality)
Industry: Contract Manufacturing Organization

Drug pipeline

3 assets

APOC

Clinical Development

Indications: Neuroendocrine tumors, Acromegaly

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Ascil Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascil Biopharm.

Explore the full profile